

NOV 30 2005



GlaxoSmithKline

## FAX

To Examiner: Brenda Libby COLEMAN Group: 1624

Company USPTO

Fax 571-273-8300

From Andrea N. Scoggins

Tel 1-919-483-9552; Facsimile: 1-919-483-7977

E-mail [andrea.n.scoggins@gsk.com](mailto:andrea.n.scoggins@gsk.com)

Date November 30, 2005 Pages including cover 5

Subject Corrected Filing Receipt

GlaxoSmithKline  
PO Box 13398  
Five Moore Drive  
Research Triangle Park  
North Carolina 27709

Tel: 919 483 2100  
[www.gsk.com](http://www.gsk.com)

Re: Application of: Rachel ANNCLIFF et. al  
U.S. Serial No.: 10/531,758 Filed: April 4, 2005  
Title: Substituted Piperazines (1, 4) Diazepines, and  
2, 5 - Diazabicyclo (2.2.1) Heptanes as Histamine  
H1 and /or H3 Antagonists or Histamine H3 reverse  
Antagonists.

Attorney Docket No.: P33126USw

### Attached:

1. Request Corrected Filing Receipt (1 page)
2. Copy of Filing Receipt (3 pages)

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Dkt. No. P33126USw

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rachel ANNCLIFF et al.

Serial No.: 10/531,758

Unit: 1615

Filed:

Examiner:

For: Substituted Piperazines (1, 4) Diazepines, and  
2, 5 - Diazabicyclo (2.2.1) Heptanes as Histamine  
H1 and/or H3 Antagonists or Histamine H3 reverse  
Antagonists.

RECEIVED  
CENTRAL FAX CENTER  
NOV 30 2005

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

2. There is an error with respect to the following data, which is:

☒ Incorrectly entered

and/or

☐ omitted.

## Error in

1. ☒ Applicant's name

## Correct data

1. Colin David Eldred, Stevenage, United Kingdom  
Yvonne C. Fogden, Stevenage, United Kingdom  
Ashley Paul Hancock, Stevenage, United Kingdom  
Thomas Daniel Heightman, Harlow, United Kingdom  
Simon Teanby Hodgson, Stevenage, United Kingdom  
Matthew J. Lindon, Stevenage, United Kingdom  
David Matthew Wilson, Harlow, United Kingdom

2. ☐ Applicant's address

3. ☒ Title

2.

3. Substituted Piperazines (1, 4) Diazepines, and  
2, 5 - Diazabicyclo (2.2.1) Heptanes as  
Histamine H1 and/or H3 Antagonists or Histamine  
H3 Reverse Antagonists.

4. ☐ Filing date

5. ☐ Serial Number

6. ☐ Foreign/PCT Application Re:


7. ☐ Other:

4.

5.

6.

7.



James P. Riek

Registration No.: 39,009

Date: November 30, 2005

GlaxoSmithKline

Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Phone: 919-483-2474

Fax: 919-483-7988

## CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being facsimile transmitted or deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: M/S XXX, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: November 30, 2005



ANDREA N. SCOGGINS

COPIED TO THE UK



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
✓ 10/531,758	04/14/2005	1615	✓ 900	P33126USW		8	1

CONFIRMATION NO. 5647

23347  
 GLAXOSMITHKLINE  
 CORPORATE INTELLECTUAL PROPERTY, MAI B475  
 FIVE MOORE DR., PO BOX 13398  
 RESEARCH TRIANGLE PARK, NC 27709-3398

## FILING RECEIPT

\*OC000000017050973\*

Date Mailed: 09/23/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

## Applicant(s)

Rachel Ancliff, Stevenage, UNITED KINGDOM;  
 Colin Eldred, Stevenage, UNITED KINGDOM;  
 Yvonne Fogden, Stevenage, UNITED KINGDOM;  
 Ashley Hancock, Stevenage, UNITED KINGDOM;  
 Thomas Heightman, Harlow, UNITED KINGDOM;  
 Heather Hobbs, Stevenage, UNITED KINGDOM;  
 Simon Hodgson, Stevenage, UNITED KINGDOM;  
 Matthew Lindon, Stevenage, UNITED KINGDOM;  
 David Wilson, Harlow, UNITED KINGDOM;

✓ **Power of Attorney:** The patent practitioners associated with Customer Number 23347.

✓ **Domestic Priority data as claimed by applicant**


This application is a 371 of PCT/EP03/11423 10/14/2003

## Foreign Applications

✓ UNITED KINGDOM 0224084,4 10/16/2002

• **Projected Publication Date:** 12/29/2005

**Non-Publication Request:** No



Early Publication Request: No

Title

Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) <sup>heptanes</sup> heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists

Preliminary Class

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

---

### LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).